Boehringer Ingelheim Venture Fund
Investor profile
Corporate VCVenture capital
Also recorded as: Boehringer Ingelheim
Deals
24
distinct rounds
Companies
18
backed
Active span
2013–2024
12 yrs
Total round €
€368M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- High-Tech Gründerfonds (HTGF)6
- NRW.BANK4
- Wellington Partners4
- Kurma Partners3
- Forbion2
- GIMV2
- IDInvest Partners2
- Oxford University Innovation Fund2
- Parkwalk Advisors2
- PPF Group2
- Seventure Partners2
- Sunstone Capital2
- AdBio partners1
- Arkin Holdings1
- Athos Capital1
- BioMedPartners1
- Caixa Capital Risc1
- Carma Fund1
- Chimera Partners1
- Coparion1
- Eli lilly and company1
- EMBL Ventures1
- Epidarex Capital1
- Evotec1
- Gilde Healthcare1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Abalos Therapeutics | Germany | 1 | €43M |
| NBE-Therapeutics | Switzerland | 3 | €41M |
| Aignostics | Germany | 1 | €31M |
| AMAL | Switzerland | 1 | €28M |
| Rigontec | Germany | 3 | €28M |
| DiogenX | France | 1 | €28M |
| Eyevensys | France | 2 | €27M |
| Brainomix | UK | 2 | €27M |
| STAT-Diagnostica | Spain | 1 | €25M |
| Imcheck Therapeutics | France | 1 | €20M |
| Topas Therapeutics | Germany | 1 | €18M |
| Metabomed | Israel | 1 | €16M |
| Dopavision | Germany | 1 | €12M |
| tacalyx | Germany | 1 | €7.0M |
| Asgard Therapeutics | Sweden | 1 | €6.0M |
| C-mo Medical Solutions | Portugal | 1 | €4.8M |
| Amal Therapeutics | Switzerland | 1 | €2.8M |
| Acousia Therapeutics | Germany | 1 | €2.5M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Abalos Therapeutics | Series A | €43M | 2021-10 |
| Aignostics | Series B | €31M | 2024-10 |
| AMAL | Series B | €28M | 2018-11 |
| DiogenX | Series A | €28M | 2023-05 |
| Eyevensys | Series B | €27M | 2020-07 |
| STAT-Diagnostica | Series C | €25M | 2016-03 |
| Imcheck Therapeutics | Other | €20M | 2017-05 |
| NBE-Therapeutics | Series C | €20M | 2020-09 |
| Brainomix | Series B | €19M | 2021-12 |
| NBE-Therapeutics | Series B | €19M | 2016-10 |